UNAUDITED CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) - USD ($)	Preferred Stock	Common Stock	Stock Payable	Paid-In Capital	Accumulated Deficit	Other Comprehensive Income	Sub Total	Noncontrolling Interest	Redeemable Non-controlling Interest	Total
Balance at Jul. 31, 2017	$ 4	$ 1,068	$ 2,168,951	$ 368,409,627	$ (445,720,566)	$ 783,150	$ (74,357,766)	$ (5,518,465)		$ (79,876,231)
Balance (in shares) at Jul. 31, 2017	3,790	1,068,100
Net Income (loss)					21,442,282		21,442,282	(313,261)		21,129,021
Investment in subsidiary by noncontrolling interest								213,403		213,403
Currency translation adjustment						9,779	9,779			9,779
Balance at Apr. 30, 2018	$ 4	$ 1,068	2,168,951	368,409,627	(424,278,284)	792,929	(52,905,705)	(5,618,323)		(58,524,028)
Balance (in shares) at Apr. 30, 2018	3,790	1,068,100
Balance at Jan. 31, 2018	$ 4	$ 1,068	2,168,951	368,409,627	(427,814,171)	779,252	(56,455,269)	(5,602,556)		(62,057,825)
Balance (in shares) at Jan. 31, 2018	3,790	1,068,100
Net Income (loss)					3,535,887		3,535,887	(103,794)		3,432,093
Investment in subsidiary by noncontrolling interest								88,027		213,403
Currency translation adjustment						13,677	13,677			9,779
Balance at Apr. 30, 2018	$ 4	$ 1,068	2,168,951	368,409,627	(424,278,284)	792,929	(52,905,705)	(5,618,323)		(58,524,028)
Balance (in shares) at Apr. 30, 2018	3,790	1,068,100
Balance at Jul. 31, 2018	$ 4	$ 22,430	2,168,951	368,388,265	(409,386,468)	798,422	(38,008,396)	(5,576,272)		(43,584,668)
Balance (in shares) at Jul. 31, 2018	79,590	22,430,121
Net Income (loss)					(4,555,490)		(4,555,490)	(1,199,822)		(5,755,312)
Investment in subsidiary by noncontrolling interest								228,789		228,789
Conversion of preferred series H	$ (3)	$ 25,200		(25,197)
Conversion of preferred series H (in shares)	(63,000)	25,200,000
Conversion of preferred series I	$ (1)	$ 6,631		(6,630)
Conversion of preferred series I (in shares)	(16,590)	6,630,644
Elimination of non-controlling interest				(6,951,015)			(6,951,015)			(6,951,015)
Issuance of common stock payable		$ 6,068	(1,967,657)	1,961,589
Issuance of common stock payable (in shares)		6,068,517
Issuance of stock options				1,530,312			1,530,312			1,530,312
Conversion of debt to equity		$ 33		14,056,080			14,056,113			14,056,113
Conversion of debt to equity (in shares)		32,881
Conversion of debt to equity - Veneto				13,929,129			13,929,129			13,929,129
Antigen dividend				(1,070,456)			(1,070,456)	1,070,456
Issuance of warrants				9,032,435			9,032,435			9,032,435
Acquisition of NCI of Regentys								9,870,762		9,870,762
Acquisition of NCI of Olaregen								11,999,559		11,999,559
Acquisition of NCI of HDS								5,565,285		5,565,285
Reclassification of equity to liability			(201,294)				(201,294)			(201,294)
Redeemable non-controlling interest									4,073,898	4,073,898
Currency translation adjustment						9,342	9,342			9,342
Balance at Apr. 30, 2019		$ 60,362		400,844,512	(413,941,958)	807,764	(12,229,320)	21,958,757	4,073,898	13,803,335
Balance (in shares) at Apr. 30, 2019		60,362,163
Balance at Jan. 31, 2019		$ 60,362	201,294	387,380,368	(403,628,069)	800,446	(15,185,599)	21,683,698	4,073,898	10,571,997
Balance (in shares) at Jan. 31, 2019		60,362,143
Net Income (loss)					(10,313,889)		(10,313,889)	(839,419)		(11,153,308)
Investment in subsidiary by noncontrolling interest								44,020		44,020
Issuance of stock options				605,467			605,467			605,467
Extinguishment of debt - Veneto				13,929,129			13,929,129			13,929,129
Antigen dividend				(1,070,456)			(1,070,456)	1,070,456
Acquisition of NCI of Olaregen								2		2
Reclassification of equity to liability			(201,294)				(201,294)			(201,294)
Currency translation adjustment						7,318	7,318			7,318
Balance at Apr. 30, 2019		$ 60,362		$ 400,844,512	$ (413,941,958)	$ 807,764	$ (12,229,320)	$ 21,958,757	$ 4,073,898	$ 13,803,335
Balance (in shares) at Apr. 30, 2019		60,362,163